Enfuvirtide
- Generic Name
- Enfuvirtide
- Brand Names
- Fuzeon
- Drug Type
- Biotech
- CAS Number
- 159519-65-0
- Unique Ingredient Identifier
- 19OWO1T3ZE
- Background
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
- Indication
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 211
- Registration Number
- NCT00128830
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
- Conditions
- Leukoencephalopathy, Progressive MultifocalHIV Infections
- First Posted Date
- 2005-07-18
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 30
- Registration Number
- NCT00120367
- Locations
- 🇫🇷
Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre, Le Kremlin Bicetre, France
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
- Conditions
- HIV Infection
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT00100984
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
- Conditions
- HIV Infections
- Interventions
- Drug: Optimized Background ARVs
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00089492
Study of Enfuvirtide in HIV-Positive Subjects
- Conditions
- HIV InfectionsAIDS
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Trimeris
- Target Recruit Count
- 26
- Registration Number
- NCT00086710
- Locations
- 🇺🇸
SFBC, Miami, Florida, United States
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 19
- Registration Number
- NCT00051831
- Locations
- 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 5
- Registration Number
- NCT00050856
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Adding New Drugs for HIV Infected Patients Failing Current Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 50
- Registration Number
- NCT00031044
- Locations
- 🇺🇸
Miami University, Miami, Florida, United States
🇺🇸Harvard (Massachusetts General Hosp), Boston, Massachusetts, United States
🇵🇷Univ of Puerto Rico, San Juan, Puerto Rico
Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00001118
- Locations
- 🇺🇸
Long Beach Memorial (Pediatric), Long Beach, California, United States
🇺🇸Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States
🇺🇸Harlem Hosp Ctr, New York, New York, United States
A Study of T-20 in HIV-Positive Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Trimeris
- Target Recruit Count
- 78
- Registration Number
- NCT00002228
- Locations
- 🇺🇸
Northwestern Univ / Infect Dis Div / Pasavant Pav 828, Chicago, Illinois, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.